Spanish adaptation of the european guidelines for the evaluation and treatment of actinic keratosis;Adaptación española de la Guía europea para la evaluación y tratamiento de la queratosis actínica

Actas Dermo-Sifiliograficas

Volumn 105, Issue 4, 2014, Pages 378-393

  Ferrandiz C ^a   Fonseca Capdevila, E ^b   Garcia Diez A ^c   Guillen Barona C ^d   Belinchon Romero I ^e   Redondo Bellon P ^f   Moreno Gimenez J C ^g   Senan R ^h  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Ctro de Atencion Primaria El Clot   (Spain)

Author keywords

Actinic keratosis; Criteria; Treatment; Treatment guidelines

Indexed keywords

ABLATION THERAPY; ACTINIC KERATOSIS; ARTICLE; CLINICAL FEATURE; EUROPE; EVIDENCE BASED PRACTICE; HEALTH CARE PLANNING; HUMAN; PRACTICE GUIDELINE; PREVALENCE; ALGORITHM; KERATOSIS, ACTINIC; SPAIN;

ALGORITHMS; EUROPE; HUMANS; KERATOSIS, ACTINIC; PRACTICE GUIDELINES AS TOPIC; SPAIN;

EID: 84899900138     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2013.11.004     Document Type: Article

References (127)

1. S.J. Salasche Epidemiology of actinic keratoses and squamous cell carcinoma J Am Acad Dermatol 42 2000 4 7
2. C. Frost, G. Williams, and A. Green High incidence and regression rates of solar keratoses in a queensland community J Invest Dermatol 115 2000 273 277
3. I. Harvey, S. Frankel, R. Marks, D. Shalom, and M. Nolan-Farrell Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study Br J Cancer 74 1996 1302 1307
4. P. Bernard, A. Dupuy, A. Sasco, P. Brun, G. Duru, and N. Nicoloyannis et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: A cross-sectional survey Dermatology 216 2008 194 199
5. L. Naldi, L. Chatenoud, R. Piccitto, P. Colombo, E.B. Placchesi, and C. La Vecchia Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004 Arch Dermatol 142 2006 722 726
6. A. Massa, R. Alves, J. Amado, E. Matos, M. Sanches, and M. Selores et al. Prevalence of cutaneous lesions in Freixo de Espada a Cinta Acta Med Port 13 2000 247 254
7. A.A. Memon, J.A. Tomenson, J. Bothwell, and P.S. Friedmann Prevalence of solar damage and actinic keratosis in a Merseyside population Br J Dermatol 142 2000 1154 1159
8. Stockfleth E, Terhorst D, Braathen L, Cribier B, Cerio R, Ferrandiz C, et al. Guideline on Actinic Keratoses, developed by the Guideline Subcommittee «Actinic Keratoses» of the European Dermatology Forum. 2011 [consultado 3 May 2013]. Disponible en: http://www.euroderm.org/images/stories/ guidelines/guideline-Management-Actinic-Keratoses-update2011.pdf
9. Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developers' handbook. 2001. Edinburgh: SIGN [consultado 3 May 2013]. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/50/index.html
10. National Institute for Clinical Excellence Guideline development methods: Information for National Collaborating Centres and Guideline Developers 2005 National Institute for Clinical Evidence London
11. D.E. Brash, A. Ziegler, A.S. Jonason, J.A. Simon, S. Kunala, and D.J. Leffell Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion J Investig Dermatol Symp Proc 1 1996 136 142
12. B.A. Lober, and C.W. Lober Actinic keratosis is squamous cell carcinoma South Med J 93 2000 650 655
13. E. Stockfleth, I. Nindl, W. Sterry, C. Ulrich, T. Schmook, and T. Meyer Human papillomaviruses in transplant-associated skin cancers Dermatol Surg 30 2004 604 609
14. G. Orth, S. Jablonska, M. Favre, O. Croissant, M. Jarzabek-Chorzelska, and G. Rzesa Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis Proc Natl Acad Sci U S A 75 1978 1537 1541
15. S. Jackson, and A. Storey E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage Oncogene 19 2000 592 598
16. S. Jackson, C. Harwood, M. Thomas, L. Banks, and A. Storey Role of bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins Genes Dev 14 2000 3065 3073
17. B. Hu, E. Castillo, L. Harewood, P. Ostano, A. Reymond, and R. Dummer et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling Cell 149 2014 1207 1220
18. N. Scola, T. Gambichler, H. Saklaoui, F.G. Bechara, D. Georgas, and M. Stucker et al. The expression of antimicrobial peptides is significantly altered in cutaneous squamous cell carcinoma and precursor lesions Br J Dermatol 167 2014 591 597
19. V. Salmon-Ehr, C. Grosieux, G. Potron, and B. Kalis Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment Dermatology 196 1998 274
20. F. Grange, D. Couilliet, B. Audhuy, S. Krzisch, P. Schlecht, and J.C. Guillaume Multiple keratosis induced by hydroxyurea Ann Dermatol Venereol 122 1995 16 18
21. D. Lerda Sister-chromatid exchange (SCE) among individuals chronically exposed to arsenic in drinking water Mutat Res 312 1994 111 120
22. B.J. Braakhuis, M.P. Tabor, J.A. Kummer, C.R. Leemans, and R.H. Brakenhoff A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications Cancer Res 63 2003 1727 1730
23. A.B. Ackerman Solar keratosis is squamous cell carcinoma Arch Dermatol 139 2003 1216 1217
24. A.B. Ackerman, and J.M. Mones Solar (actinic) keratosis is squamous cell carcinoma Br J Dermatol 155 2006 9 22
25. S.T. Guenthner, R.M. Hurwitz, L.J. Buckel, and H.R. Gray Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation J Am Acad Dermatol 41 1999 443 448
26. J. Jorizzo, J. Weiss, K. Furst, C. VandePol, and S.F. Levy Effect of a 1-week treatment with.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial Arch Dermatol 140 2004 813 816
27. E. Stockfleth, C. Ferrandiz, J.J. Grob, I. Leigh, H. Pehamberger, and H. Kerl Development of a treatment algorithm for actinic keratoses: A European consensus Eur J Dermatol 18 2008 651 659
28. M.A. Mittelbronn, D.L. Mullins, F.A. Ramos-Caro, and F.P. Flowers Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma Int J Dermatol 37 1998 677 681
29. J. Rowert-Huber, M.J. Patel, T. Forschner, C. Ulrich, J. Eberle, and H. Kerl et al. Actinic keratosis is an early in situ squamous cell carcinoma: A proposal for reclassification Br J Dermatol 156 Suppl 3 2007 8 12
30. M. Ulrich, A. Maltusch, J. Rowert-Huber, S. Gonzalez, W. Sterry, and E. Stockfleth et al. Actinic keratoses: Non-invasive diagnosis for field cancerisation Br J Dermatol 156 Suppl 3 2007 13 17
31. R.M. Szeimies, and M. Landthaler Photodynamic therapy and fluorescence diagnosis of skin cancers Recent Results Cancer Res 160 2002 240 245
32. A. Green, and D. Battistutta Incidence and determinants of skin cancer in a high-risk Australian population Int J Cancer 46 1990 356 361
33. D. Czarnecki, C.J. Meehan, F. Bruce, and G. Culjak The majority of cutaneous squamous cell carcinomas arise in actinic keratoses J Cutan Med Surg 6 2002 207 209
34. P.J. Quaedvlieg, E. Tirsi, M.R. Thissen, and G.A. Krekels Actinic keratosis: How to differentiate the good from the bad ones? Eur J Dermatol 16 2006 335 339
35. R. Marks, P. Foley, G. Goodman, B.H. Hage, and T.S. Selwood Spontaneous remission of solar keratoses: The case for conservative management Br J Dermatol 115 1986 649 655
36. M. Trakatelli, C. Ulrich, V. del Marmol, S. Euvrard, E. Stockfleth, and D. Abeni Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions Br J Dermatol 156 Suppl 3 2007 1 7
37. A. Fuchs, and E. Marmur The kinetics of skin cancer: Progression of actinic keratosis to squamous cell carcinoma Dermatol Surg 33 2007 1099 1101
38. R.G. Glogau The risk of progression to invasive disease J Am Acad Dermatol 42 2000 23 24
39. E. Stockfleth, T. Meyer, B. Benninghoff, S. Salasche, L. Papadopoulos, and C. Ulrich et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses Arch Dermatol 138 2002 1498 1502
40. C. Ulrich, E. Christophers, W. Sterry, T. Meyer, and E. Stockfleth Skin diseases in organ transplant patients Hautarzt 53 2002 524 533
41. G.J. Chen, S.R. Feldman, P.M. Williford, E.J. Hester, S.H. Kiang, and I. Gill et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer Dermatol Surg 31 2005 43 47
42. C. Ulrich, A. Degen, M.J. Patel, and E. Stockfleth Sunscreens in organ transplant patients Nephrol Dial Transplant 23 2008 1805 1808
43. C. Ulrich, J.S. Jurgensen, A. Degen, M. Hackethal, M. Ulrich, and M.J. Patel et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: A 24 months, prospective, case-control study Br J Dermatol 161 Suppl 3 2009 78 84
44. E. Berardesca, M. Bertona, K. Altabas, V. Altabas, and E. Emanuele Reduced ultraviolet-induced DNA damage and apoptosis in human skin with topical application of a photolyase-containing DNA repair enzyme cream: Clues to skin cancer prevention Mol Med Report 5 2012 570 574
45. S.C. Thompson, D. Jolley, and R. Marks Reduction of solar keratoses by regular sunscreen use N Engl J Med 329 1993 1147 1151
46. S. Darlington, G. Williams, R. Neale, C. Frost, and A. Green A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses Arch Dermatol 139 2003 451 455
47. A. Green, G. Williams, R. Neale, V. Hart, D. Leslie, and P. Parsons et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial Lancet 354 1999 723 729
48. M.F. Naylor, A. Boyd, D.W. Smith, G.S. Cameron, D. Hubbard, and K.H. Neldner High sun protection factor sunscreens in the suppression of actinic neoplasia Arch Dermatol 131 1995 170 175
49. R.M. Szeimies, S. Karrer, S. Radakovic-Fijan, A. Tanew, P.G. Calzavara-Pinton, and C. Zane et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study J Am Acad Dermatol 47 2002 258 262
50. C. Serra-Guillen, E. Nagore, L. Hueso, V. Traves, F. Messeguer, and O. Sanmartin et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: Clinical and histologic outcomes J Am Acad Dermatol 66 2012 e131 e137
51. E. Stockfleth, and H. Kerl Guidelines for the management of actinic keratoses Eur J Dermatol 16 2006 599 606
52. S.M. Dinehart The treatment of actinic keratoses J Am Acad Dermatol 42 2000 25 28
53. Dirschka T, Dominicus R, Lars K, Rodriguez R, Willers C, Simon JC. Long term efficacy and recurrence of topical.5% 5-fluorouracil with 10% salicylic acid for actinic keratosis compared to cryotherapy. A prospective, active, controlled, randomized, exploratory study [Poster]. En: 6 th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers and 8 th European Association of Derma Oncology Congress. 2012. http://www.sbc-congresos.com/pdf2012/ programmelanoma2012.pdf.
54. R.R. Lubritz, and S.A. Smolewski Cryosurgery cure rate of actinic keratoses J Am Acad Dermatol 7 1982 631 632
55. K.E. Thai, P. Fergin, M. Freeman, C. Vinciullo, D. Francis, and L. Spelman et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses Int J Dermatol 43 2004 687 692
56. C.C. Zouboulis, and H. Rohrs Cryosurgical treatment of actinic keratoses and evidence-based review Hautarzt 56 2005 353 358
57. Malvehy J, Roldan R, Iglesias P, Díaz A, Puig S. Reflectance confocal microscopy evaluation of the changes induced by the treatment with Solaraze® (diclofenac 3% in 2.5% hyaluronic acid gel) in the actinic field cancerisation. [Poster] En: 6 thWorld Meeting of Interdisciplinary Melanoma/Skin Cancer Centers and 8 th European Association of Derma Oncology Congress. 2012. http://www.sbc-congresos.com/pdf2012/program-melanoma2012.pdf.
58. L.F. Fecker, E. Stockfleth, I. Nindl, C. Ulrich, T. Forschner, and J. Eberle The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs) Br J Dermatol 156 Suppl 3 2007 25 33
59. L.F. Fecker, E. Stockfleth, F.K. Braun, P.M. Rodust, C. Schwarz, and A. Kohler et al. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP J Invest Dermatol 130 2014 2098 2109
60. Y.J. Jung, J.S. Isaacs, S. Lee, J. Trepel, and L. Neckers IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis FASEB J 17 2003 2115 2117
61. J. Eberle, L.F. Fecker, T. Forschner, C. Ulrich, J. Rowert-Huber, and E. Stockfleth Apoptosis pathways as promising targets for skin cancer therapy Br J Dermatol 156 Suppl 3 2007 18 24
62. P.M. Rodust, L.F. Fecker, E. Stockfleth, and J. Eberle Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w Exp Dermatol 21 2014 520 525
63. A. Maltusch, J. Rowert-Huber, C. Matthies, S. Lange-Asschenfeldt, and E. Stockfleth Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis J Dtsch Dermatol Ges 9 2014 1011 1017
64. R.L. Miller, J.F. Gerster, M.L. Owens, H.B. Slade, and M.A. Tomai Imiquimod applied topically: A novel immune response modifier and new class of drug Int J Immunopharmacol 21 1999 1 14
65. Zyclara®, ficha técnica. Agencia Española del Medicamento y Productos Sanitarios [acceso 3 May 2013]. Disponible en: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/ human/002387/WC500132261.pdf
66. C.W. Hanke, K.R. Beer, E. Stockfleth, J. Wu, T. Rosen, and S. Levy Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles J Am Acad Dermatol 62 2014 573 581
67. N. Swanson, W. Abramovits, B. Berman, J. Kulp, D.S. Rigel, and S. Levy Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles J Am Acad Dermatol 62 2014 582 590
68. S.M. Ogbourne, A. Suhrbier, B. Jones, S.J. Cozzi, G.M. Boyle, and M. Morris et al. Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell death Cancer Res 64 2004 2833 2839
69. Picato® ficha técnica. Agencia Española del Medicamento y Productos Sanitarios [acceso 3 May 2013]. Disponible en: http://www.ema. europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/002275/ WC500135327.pdf
70. K.B. Gorden, K.S. Gorski, S.J. Gibson, R.M. Kedl, W.C. Kieper, and X. Qiu et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 J Immunol 174 2005 1259 1268
71. M. Moriarty, J. Dunn, A. Darragh, R. Lambe, and I. Brick Etretinate in treatment of actinic keratosis. A double-blind crossover study Lancet 1 1982 364 365
72. T.C. Yu, Z. Rahman, and B.S. Ross Actinic keratoses - surgical and physical therapeutic modalities Cutis 71 2003 381 384
73. R.V. Carneiro, M.N. Sotto, L.S. Azevedo, L.E. Ianhez, and E.A. Rivitti Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin Clin Transplant 19 2005 115 121
74. F. Ismail, L. Mitchell, D. Casabonne, A. Gulati, R. Newton, and C.M. Proby et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness Br J Dermatol 155 2006 916 925
75. M.J. Fuente, M. Sabat, J. Roca, R. Lauzurica, M.T. Fernandez-Figueras, and C. Ferrandiz A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients Br J Dermatol 149 2003 1221 1226
76. C. Ferrandiz, M.J. Fuente, M. Ribera, I. Bielsa, M.T. Fernandez, and R. Lauzurica et al. Epidermal dysplasia and neoplasia in kidney transplant recipients J Am Acad Dermatol 33 1995 590 596
77. T.M. Johnson, D. Ratner, and B.R. Nelson Soft tissue reconstruction with skin grafting J Am Acad Dermatol 27 1992 151 165
78. J.Q. Del Rosso An update on newer topical therapies for actinic keratoses: Advances and applications J Drugs Dermatol 2 2003 35 39
79. T. Ehrig, C. Cockerell, D. Piacquadio, and S. Dromgoole Actinic keratoses and the incidence of occult squamous cell carcinoma: A clinical-histopathologic correlation Dermatol Surg 32 2006 1261 1265
80. G. Hadley, S. Derry, and R.A. Moore Imiquimod for actinic keratosis: Systematic review and meta-analysis J Invest Dermatol 126 2006 1251 1255
81. C.M. Perrett, J.M. McGregor, J. Warwick, P. Karran, I.M. Leigh, and C.M. Proby et al. Treatment of post-transplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy Br J Dermatol 156 2007 320 328
82. D.E. Rowe, R.J. Carroll, and C.L. Day Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection J Am Acad Dermatol 26 1992 976 990
83. C. Serra-Guillen, E. Nagore, L. Hueso, B. Llombart, C. Requena, and O. Sanmartin et al. A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate Br J Dermatol 164 2011 429 433
84. Z. Petrovich, R.G. Parker, G. Luxton, H. Kuisk, and J. Jepson Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients Radiother Oncol 8 1987 11 17
85. G.F. Graham Cryosurgery in the management of cutaneous malignancies Clin Dermatol 19 2001 321 327
86. C. Ulrich, J. Bichel, S. Euvrard, B. Guidi, C.M. Proby, and P.C. van de Kerkhof et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients Br J Dermatol 157 Suppl 2 2007 25 31
87. C. Ulrich, M. Hackethal, M. Ulrich, A. Howorka, T. Forschner, and W. Sterry et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: A series of six cases Br J Dermatol 156 Suppl 3 2007 40 42
88. N. Krawtchenko, J. Roewert-Huber, M. Ulrich, I. Mann, W. Sterry, and E. Stockfleth A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up Br J Dermatol 157 Suppl 2 2007 34 40
89. B.U. Meijer, and F.B. de Waard-van der Spek Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream) Contact Dermatitis 57 2007 58 60
90. S. Levy, K. Furst, and W. Chern A pharmacokinetic evaluation of.5% and 5% fluorouracil topical cream in patients with actinic keratosis Clin Ther 23 2001 908 920
91. Solaraze® ficha técnica. Agencia Española del Medicamento y Productos Sanitarios [acceso 3 May 2013]. Disponible en: http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo= 73714&formato=pdf&formulario=FICHAS&file=ficha.pdf
92. C. Nelson, and D. Rigel Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: One-year evaluation J Clin Aesthet Dermatol 2 2009 20 25
93. J.E. Wolf Jr., J.R. Taylor, E. Tschen, and S. Kang Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses Int J Dermatol 40 2001 709 713
94. M.J. Patel, and E. Stockfleth Does progression from actinic keratosis and Bowen's disease end with treatment: Diclofenac 3% gel, an old drug in a new environment? Br J Dermatol 156 Suppl 3 2007 53 56
95. L. Kowalzick, and H. Ziegler Photoallergic contact dermatitis from topical diclofenac in Solaraze gel Contact Dermatitis 54 2006 348 349
96. C. Ulrich, A. Johannsen, J. Rowert-Huber, M. Ulrich, W. Sterry, and E. Stockfleth Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses Eur J Dermatol 20 2010 482 488
97. Aldara® ficha técnica. Agencia Española del Medicamento y Productos Sanitarios [acceso 3 May 2013]. Disponible en: http://www.ema. europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/000179/ WC500023122.pdf
98. M. Lebwohl, S. Dinehart, D. Whiting, P.K. Lee, N. Tawfik, and J. Jorizzo et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase iii, randomized, double-blind, parallel group, vehicle-controlled trials J Am Acad Dermatol 50 2004 714 721
99. E. Stockfleth, E. Christophers, B. Benninghoff, and W. Sterry Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: A long-term follow-up study Arch Dermatol 140 2004 1542
100. E. Stockfleth, W. Sterry, M. Carey-Yard, and J. Bichel Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head Br J Dermatol 157 Suppl 2 2007 41 46
101. A. Alomar, J. Bichel, and S. McRae Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head Br J Dermatol 157 2007 133 141
102. J. Jorizzo, S. Dinehart, R. Matheson, J.K. Moore, M. Ling, and T.L. Fox et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head J Am Acad Dermatol 57 2007 265 268
103. P.K. Lee, W.B. Harwell, K.H. Loven, T.J. Phillips, D.A. Whiting, and K.L. Andres et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream Dermatol Surg 31 2005 659 664
104. L.R. Braathen, R.M. Szeimies, N. Basset-Seguin, R. Bissonnette, P. Foley, and D. Pariser et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. International Society for Photodynamic Therapy in Dermatology, 2005 J Am Acad Dermatol 56 2007 125 143
105. C.A. Morton, S.B. Brown, S. Collins, S. Ibbotson, H. Jenkinson, and H. Kurwa et al. Guidelines for topical photodynamic therapy: Report of a workshop of the British Photodermatology Group Br J Dermatol 146 2002 552 567
106. E.H. Tschen, D.S. Wong, D.M. Pariser, F.E. Dunlap, A. Houlihan, and M.B. Ferdon Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase IV multicentre clinical trial with 12-month follow up Br J Dermatol 155 2006 1262 1269
107. S. Radakovic-Fijan, U. Blecha-Thalhammer, H. Kittler, H. Honigsmann, and A. Tanew Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: A randomized, observer-blinded, intrapatient, comparison study J Am Acad Dermatol 53 2005 823 827
108. P. Babilas, M. Landthaler, and R.M. Szeimies Photodynamic therapy in dermatology Eur J Dermatol 16 2006 340 348
109. Metvix® ficha técnica. Agencia Española del Medicamento y Productos Sanitarios [acceso 3 May 2013]. Disponible en: http://www.aemps.gob. es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=64968&formato= pdf&formulario=FICHAS&file=ficha.pdf
110. R. Kaufmann, L. Spelman, W. Weightman, J. Reifenberger, R.M. Szeimies, and E. Verhaeghe et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities Br J Dermatol 158 2008 994 999
111. A.K. Gupta The management of actinic keratoses in the United States with topical fluorouracil: A pharmacoeconomic evaluation Cutis 70 2002 30 36
112. N. Lawrence, S.E. Cox, C.J. Cockerell, R.G. Freeman, and P.D. Cruz Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses Arch Dermatol 131 1995 176 181
113. A.K. Gupta, V. Davey, and H. McPhail Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies J Cutan Med Surg 9 2005 209 214
114. M. Rhavar, S.A. Lamel, and H.I. Maibach Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: An overview Immunotherapy 4 2014 939 945
115. M.R. Johnson, A. Hageboutros, K. Wang, L. High, J.B. Smith, and R.B. Diasio Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil Clin Cancer Res 5 1999 2006 2011
116. Actikerall® ficha técnica. Agencia Española del Medicamento y Productos Sanitarios [acceso 3 May 2013]. Disponible en: http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo= 77675&formato=pdf&formulario=FICHAS&file=ficha.pdf
117. M. Schlaak, and J.C. Simon Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid - pilot study J Dtsch Dermatol Ges 8 2014 174 178
118. M. Lebwohl, N. Swanson, L.L. Anderson, A. Melgaard, Z. Xu, and B. Berman Ingenol mebutate gel for actinic keratosis N Engl J Med 366 2012 1010 1019
119. Ingenol mebutate gel for actinic keratosis-First line National Institute for Health Research (NIHR)-National Horizon Scanning Centre Company Publication; 2010.
120. M. Lebwohl, S. Shumack, L. Stein Gold, A. Melgaard, T. Larsson, and S.K. Tyring Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses JAMA Dermatol 149 2013 666 670
121. R.M. Szeimies, J. Bichel, J.P. Ortonne, E. Stockfleth, J. Lee, and T.C. Meng A phase ii dose-ranging study of topical resiquimod to treat actinic keratosis Br J Dermatol 159 2008 205 210
122. B. Berman, L. Bienstock, L. Kuritzky, E.J. Mayeaux Jr., and S.K. Tyring Actinic keratoses: Sequelae and treatments. Recommendations from a consensus panel J Fam Pract 55 Suppl 2006 1 8
123. R.A. Schwartz, T.M. Bridges, A.K. Butani, and A. Ehrlich Actinic keratosis: An occupational and environmental disorder J Eur Acad Dermatol Venereol 22 2008 606 615
124. J.V. Schmitt, and H.A. Miot Actinic keratosis: A clinical and epidemiological revision An Bras Dermatol 87 2014 425 434
125. N.A. Fenske, J. Spencer, and F. Adam Actinic keratoses: Past, present and future J Drugs Dermatol 9 2014 s45 s49
126. P.T. Strickland, B.C. Vitasa, S.K. West, F.S. Rosenthal, E.A. Emmett, and H.R. Taylor Quantitative carcinogenesis in man: Solar ultraviolet B dose dependence of skin cancer in Maryland watermen J Natl Cancer Inst 81 1989 1910 1913
127. S. Pandey, S.E. Mercer, K. Dallas, P.O. Emanuel, and G. Goldenberg Evaluation of the prognostic significance of follicular extension in actinic keratoses J Clin Aesthet Dermatol 5 2014 25 28